Grand Life Sciences Group Co., Ltd.
Grand Life Sciences Group Co., Ltd. (hereinafter
referred to as "GLS ") is a modern pharmaceutical enterprise group, which
integrates R&D, production and sales, and focuses on immunity, infection,
severe disease, blood system, digestion and wound management, etc. The group
has R&D centers and production bases in more than ten cities including
Beijing, Chengdu, Hangzhou, Shenyang, Wuhan, Chongqing, Nanjing, Zhengzhou,
Yantai, Anshan, etc., and is committed to the research and development of
high-end blood products, chemical drugs, new recombinant vaccines, nano-targeted
preparations, degradable medical devices and high-value raw materials.
In the field of blood products, GLS owns Yuanda
Shuyang Pharmaceutical Co., Ltd, one of the top 20 biopharmaceutical companies
in China, and the production capacity of its newly built modern factory ranks
first in Asia and among the top 10 in the world. The factory not only complies
with Chinese GMP standards, but also meets EU and WHO standards. Shuyang
products have covered the domestic market and exported to more than 10 countries.
In 2021, with the approval of the National Medical Products Administration
(NMPA) for the human fibrinogen product, Yuanda Shuyang Pharmaceutical has
taken an important step in the field of blood coagulation factors. In the
future, it will focus on the development of the full product line of blood
products and continue to dig deeper in rare diseases.
In the field of chemical medicine, GLS relies on the
four major industrial bases of Grand Life Sciences (Liaoning), Grand Life Sciences
(Wuhan), Penglai Nuokang and Liaoning Weibang. The company gives full play to
the advantages of large industrial foundation and the raw materials-preparations
integration to create nano-target R&D center, enzymatic engineering and
polymer material R&D platform, API base and Peruvian snake venom supply
base, and is committed to providing original biological drugs, emulsions, high-end
preparation products and biodegradable medical devices. Focus on developing
perioperative product groups, including hemostasis, anesthesia, analgesia, and
anticoagulant drugs. Among them, Hemocoagulase Bothrops Atrox for Injection is
the product with the largest share in the domestic hemostatic market,
Flurbiprofen Axetil is the first domestically-made targeted analgesic
injection, and Collagenase Ointment is currently the only enzymatic debridement
drug officially approved at home and abroad.
As a well-known pharmaceutical manufacturer in China, Grand Life Sciences (Liaoning) Co., Ltd. aims to provide high-quality and competitive pharmaceuticals to people around the world, including hemostatic products, analgesic products, anesthesia products, nutritional supplements, etc.
2023 07/14